# Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis

> **NCT00656539** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 20 (estimated)

## Conditions studied

- Blepharitis

## Interventions

- **DRUG:** AzaSite®

## Key facts

- **NCT ID:** NCT00656539
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-11
- **Final completion:** —
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2011-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00656539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00656539, "Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00656539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*